参考文献/References:
[1] LI Z Y, Gao X Y. Looking back 2018--focused on gastric cancer[J]. Chinese Journal of Gastrointestinal Surgery, 2019, 22(1): 1-8.[2] HALL C, CLARKE L, PAL A, et al. A review of the role of carcinoembryonic antigen in clinical practice[J]. Annals of Coloproctology, 2019, 35(6): 294-305.[3] MATSUOKA Y, MATSUO Y, OKAMOTO N, et al. Highly effective extraction of carcinoembryonic antigen with phosphatidylinositol-specific phospholipase C[J]. Tumor Biology, 1991, 12(2): 91-98.[4] ALVES L B, TSUKAZAN M T, SERAFIM A E, et al. Prognostic value of carcinoembryonic antigen levels in transoperative peritoneal lavage in patients with gastric cancer[J]. Arquivos Brasileiros de Cardiologia, 2018, 31(1): e1358.[5] SCARA S, BOTTONI P, SCATENA R. C A: Biochemical and Clinical Aspects[J]. Advances in Experimental Medicine and Biology, 2015, 867: 247-260.[6] ZHU Y Y, ZHAO W J, MAO G X. Perioperative lymphocyte-to-monocyte ratio changes plus CA199 in predicting the prognosis of patients with gastric cancer[J]. Journal of Gastrointestinal Oncology, 2022, 13(3): 1007-1021.[7] JING R R, CUI M, JU S Q, et al. The changes and clinical significance of preoperative and postoperative serum CEA and CA19-9 in gastric cancer[J]. Clinical Laboratory, 2020, 66(4): 569-577. [8] LI M X, XUE F, YANG J, et al. Correlation between tumor marker CA72-4 and prognosis of patients with gastric cancer: A protocol for systematic review and meta-analysis[J]. Medicine, 2020, 99(52): e23723.[9] JOHNSON V G, SCHLOM J, PATERSON A J, et al. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3[J]. Cancer Research, 1986, 46(2): 850-857.[10] 彭方兴，袁三英，吴宸，等. 胃癌患者手术前后外周血D-二聚体与CA724水平测定及意义[J]. 海南医学，2016，27(22): 3648-3651.[11] JING J, GE M, YANG Z Q, et al. Spatial distribution characteristics of tumor marker CA724 reference values in China[J]. Cancer Medicine, 2019, 8(9): 4465-4474. [12] CHEN X Z, HUANG C Z, HU W X, et al. Gastric cancer screening by combined determination of serum helicobacter pylori antibody and pepsinogen concentrations: ABC method for gastric cancer screening[J]. Chinese Medical Journal, 2018, 131(10): 1232-1239.[13] LIU W J, SUN Y X, YUAN Y L. Analysis of serum gastrin-17 and Helicobacter pylori antibody in healthy Chinese population[J]. Journal of Clinical Laboratory Analysis, 2020, 34(12): e23518.[14] YU G, WANG G X, WANG H G, et al. The value of detecting pepsinogen and gastrin-17 levels in serum for pre-cancerous lesion screening in gastric cancer[J]. Neoplasma, 2019, 66(4): 637-640. [15] GERDES J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies[J]. Seminars in Cancer Biology, 1990, 1(3): 199-206.[16] ZHU X H, CHEN L, HUANG B H, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer[J]. Scientific Reports , 2020, 10(1): 225.[17] SEO S H, KIM K H, OH S H, et al. Ki-67 labeling index as a prognostic marker in advanced stomach cancer[J]. Annals of Surgical Treatment and Research, 2019, 96(1): 27-33. [18] LI S M, LI B Z, WANG X J, et al. Identification of sensitivity predictors of neoadjuvant chemotherapy for the treatment of adenocarcinoma of gastroesophageal junction[J]. Oncology Research, 2017, 25(1): 93-97.[19] CONNELL C M, DOHERTY G J. Activating HER2 mutations as emerging targets in multiple solid cancers[J]. ESMO Open, 2017, 2(5): e000279.[20] ADAMCZYK A, GRELA-OJEWODA A, DOMAGALA-HADUCH M, et al. Proteins involved in HER2 signalling pathway, their relations and influence on metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting[J]. Journal of Cancer, 2017, 8(1): 131-139.[21] VRANIC S, BESLIJA S, GATSLICA Z. Targeting HER2 expression in cancer: New drugs and new indications[J]. Bosnian Journal of Basic Medical Sciences, 2021, 21(1): 1-4. [22] GRENDA A, WOJAS-KRAWCZYK K, SKOCZYLAS T, et al. HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery[J]. BMC Gastroenterology, 2020, 20(1): 382. [23] LI Q, LV M Z, JIANGH Q, et al. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy[J]. Journal of Cancer Research and Clinical Oncology, 2020, 146(1): 287-295.[24] XU M J, JOHNSON D E, GRANDIS J R. EGFR-targeted therapies in the post-genomic era[J]. Cancer and Metastasis Reviews, 2017, 36(3): 463-473.[25] CHO J. Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective[J]. BMB Reports, 2020, 53(3): 133-141. [26] LIAO J B, LEE H P, FU H T, et al. Assessment of EGFR and ERBB2 (HER2) in gastric and gastroesophageal carcinomas: EGFR amplification is associated with a worse prognosis in early stage and well to moderately differentiated carcinoma[J]. Mmunohistochemistry and Molecular Morphology, 2018, 26(6): 374-382.[27] MARON S B, ALPERT L, KWAK H A, et al. Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma[J]. Cancer Discovery, 2018, 8(6): 696-713. [28] ZHEN Y, GUANG H L, XIE F Z. Knockdown of EGFR inhibits growth and invasion of gastric cancer cells[J]. Cancer Gene Therapy, 2014, 21(11): 491-497[29] MELINCOVICI C S, BOSCA A B, ?SMAN S, et al. Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis[J]. Romanian Journal of Morphology and Embryology, 2018, 59(2): 455-467. [30] ABDEL-RAHMAN O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects[J]. Critical Reviews in Oncology/Hematology, 2015, 93(1): 18-27.[31] SUN C, MEZZADRA R, SCHUMACHER T N. Regulation and function of the PD-L1 checkpoint[J]. Immunity, 2018, 48(3): 434-452. [32] CAI J J, QI Q, QIAN X M, et al. The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer[J]. Journal of Cancer Research and Clinical Oncology, 2019, 145(6): 1377-1385.[33] SHIGEMORI T, TOIYAMA Y, OKUGAWA Y, et al. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression[J]. Annals of Surgical Oncology, 2019, 26(3): 876-883. [34] ZENG Y Q, RONG H M, XU J W, et al. DNA methylation: an important biomarker and therapeutic target for gastric cancer[J]. Frontiers in Genetics, 2022, 13: 823905.[35] MAHMOUD A M, ALI M M. Methyl donor micronutrients that modify DNA methylation and cancer outcome[J]. Nutrients, 2019, 11(3): 608. [36] USUI G, MATSUSAKA K, MANO Y, et al. DNA methylation and genetic aberrations in gastric cancer[J]. Digestion, 2021, 102(1): 25-32. [37] MAEDA M, NAKJIMA T, ODA I, et al. High impact of methylation accumulation on metachronous gastric cancer: 5-year follow-up of a multicentre prospective cohort study[J]. Gut, 2017, 66(9): 1721-1723. [38] KHAN A Q, AHMED E I, ELAREER N R, et al. Role of miRNA-regulated cancer stem cells in the Pathogenesis of Human Malignancies[J]. Cells, 2019, 8(8): 840. [39] CORREIA DE SOUSA M, GJOEGJIEVA M, DOLICKS D, et al. Deciphering miRNAs’ Action through miRNA Editing[J]. International Journal of Molecular Sciences, 2019, 20(24): 6249. [40] HU M L, ZHU S X, XIONG S W, et al. MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer[J]. Oncology Reports, 2019, 41(3): 1439-1454. [41] TAN H D, ZHANG S Y, ZHANG J, et al. Long non-coding RNAs in gastric cancer: New emerging biological functions and therapeutic implications[J]. Theranostics, 2020, 10(19): 8880-8902. [42] ZHUANG C L, MA Q, ZHUANG C S, et al. LncRNA GClnc1 promotes proliferation and invasion of bladder cancer through activation of MYC[J]. FASEB Journal, 2019, 33(10): 11045-11059. [43] CAO H L, LIU Z J, HUANG P L, et al. lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206[J]. European Review for Medical and Pharmacological Sciences, 2019, 23(3): 1012-1021.[44] ZHANG G, LI S W, LU J F, et al. LncRNA MT1JP functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer[J]. Molecular Cancer, 2018, 17(1): 87.[45] KOLAKOFSKY D. Isolation and characterization of Sendai virus DI-RNAs[J]. Cell, 1976, 8(4): 547-555.[46] DANG Y, OU X J, ZHANG F, et al. Circular RNAs expression profiles in human gastric cancer[J]. Scientific Reports, 2017, 7(1): 9060. [47] LUO Z, RONG Z Y, ZHANG J M, et al. Circular RNA circCCDC9 acts as a miR-6792-3p sponge to suppress the progression of gastric cancer through regulating CAV1 expression[J]. Molecular Cancer, 2020, 19(1): 86. [48] DING L X, ZHAO Y Y, DANG S W, et al. Circular RNA circ-DONSON facilitates gastric cancer growth and invasion via NURF complex dependent activation of transcription factor SOX4[J]. Molecular Cancer, 2019, 18(1): 45.